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Introduction: “Molly” is a street name for pure 3,4-methylenedioxymethamphetamine, an amphetamine derivative
which acts by enhancing the release of neurotransmitters such as serotonin, dopamine and norepinephrine. This
produces euphoria, increased sensory awareness and central stimulation that make it a popular club drug.
Nevertheless, it is also associated with serious side effects. We report an unusual case of rapid multiorgan failure
after ingestion of “Molly”. Unlike previously described patterns of 3,4-methylenedioxymethamphetamine-related
organ failure, our case does not appear to be related to hyperthermia, rhabdomyolysis or hyponatremia.
Case presentation: A 24-year-old Hispanic man presented to our hospital with an episode of seizure and subsequently
developed acute kidney injury, respiratory failure requiring mechanical ventilation and congestive heart failure after
ingestion of “Molly”. He rapidly recovered with supportive care and was discharged home.
Conclusions: The spectrum of complications associated with 3,4-methylenedioxymethamphetamine is wide and
patient presentation may vary. Moreover, there appears to be multiple mechanisms involved in organ failure. Drug
toxicity should be suspected while evaluating a patient with multisystem organ failure of unclear etiology. Treatment is
generally supportive sometimes requiring mechanical ventilation and hemodialysis. Nevertheless, complete reversal of
organ failure can be expected.
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“Molly” is a new club drug gaining popularity in the last
decade in all-night dance events and music festivals. The
name “Molly” is derived from the term “molecule” and is
supposedly the pure form of 3,4-methylenedioxymetham-
phetamine (MDMA) which was previously popular as
“ecstasy”. It is usually distributed as a capsule containing
the crystalline powder form of MDMA; it has stimulant
and hallucinogenic properties resulting in mood enhance-
ment and euphoria. “Molly” is perceived to be safer than
ecstasy because it lacks adulterants, and like ecstasy has
limited addictive potential [1,2]. It is now clear that there* Correspondence: truptivakde@gmail.com
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several reported cases of death. We report a case of rap-
idly reversible multiorgan failure after ingestion of
“Molly”.Case presentation
A 24-year-old Hispanic man presented after a witnessed
tonic–clonic seizure with urinary incontinence that re-
solved after lorazepam administration. He had a remote
history of seizures but was not on any medications. He
was postictal, afebrile and tachycardic with a pulse of 124
beats per minute (bpm) and blood pressure (BP) of 144/
66mmHg. Initial laboratory was remarkable for a lactate
of 17mmoles/L, which resolved rapidly. A routine urine
toxicology screen was positive for cannabinoids and
benzodiazepines and negative for cocaine, phencyclidine,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Post-intubation chest X-ray demonstrating diffuse
bilateral alveolar infiltrates left more than right.
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of abdominal pain, diarrhea, vomiting and developed pro-
gressive agitation and confusion. His lipase level was nor-
mal; however, his serum creatinine had increased from 1.4
to 4.3g/dL and subsequently increased further (Table 1).
Within a few hours his respiratory distress worsened,
becoming hypoxic with an arterial saturation of 70%. Also
noted were a fever of 38.89°C (102°F), heart rate of
140bpm, and BP of 163/104mmHg. After failing a trial of
non-invasive ventilation, he was intubated. A chest X-ray
revealed bilateral infiltrates (Figure 1). He remained hyp-
oxemic after intubation requiring 100% fraction of in-
spired oxygen. Despite not meeting compliance criteria
for acute respiratory distress syndrome his oxygenation
responded to high positive end-expiratory pressure. Anti-
biotics were initiated for possible pneumonia. Bron-
choscopy revealed normal airways and clear secretions,
not compatible with aspiration or bacterial pneumonia.
Bronchoalveolar lavage was performed. Subsequently, an
echocardiogram demonstrated an ejection fraction of 30%
with wall motion abnormalities. Bronchoscopy and echo-
cardiogram findings suggested the etiology of hypoxemic
respiratory failure was most likely fluid overload. The
etiology for acute kidney injury (AKI) and congestive heart
failure (CHF) was unclear. After three sessions of hemo-
dialysis, his oxygenation, urine output, and creatinine
levels improved. He was extubated on hospital day eight
allowing further history. Apparently several hours prior to
symptom onset he had consumed the street drug “Molly”
with alcohol, marijuana, and “purple drank”, a slang term
for a drink containing codeine and promethazine. No fur-
ther hemodialysis was required and a repeat echocardio-
gram demonstrated normalization of his left ventricular
function. He was discharged home on day twelve of
hospitalization.Table 1 Pertinent laboratory values by hospital days
Day of hospitalization Day 0 Day 3 Day 12
pH 7.09 7.42 7.45
Carbon dioxide partial pressure 38.9 26.7 33.9
Oxygen partial pressure 112 43.8 78.7
Serum bicarbonate (mEq/L) 11 21 23
Lactic acid (mmoles/L) 17 3.6 0.9
Blood urea nitrogen (g/dL) 12 43 35
Serum creatinine (g/dL) 1.4 8.2 1.7
Serum sodium (mEq/L) 137 129 141
Potassium (mEq/L) 4.0 4.0 3.7
Creatine kinase (units/L) 473 863 223
Hemoglobin (g/dL) 15 13.5 12.8
White blood cell (k/μL) 17.8 12.2 14.1
Platelets (k/μL) 420 259 328Discussion
In summary, our patient was a young man presenting with
a seizure and subsequent multiorgan failure. Several hy-
potheses were considered to explain his presentation in-
cluding aspiration pneumonitis, severe sepsis, neuroleptic
malignant syndrome, rhabdomyolysis leading to AKI and
collagen vascular disease with diffuse alveolar hemorrhage.
There was no clear source of infection and all cultures in-
cluding bronchoalveolar lavage were negative. Although
he did receive one dose of haloperidol intravenously for
his agitation on day 1, neuroleptic malignant syndrome
was unlikely as he was only briefly febrile, there was no
rigidity and creatine kinase levels were only mildly ele-
vated. Collagen vascular disease seemed unlikely, as all his
serologic markers were negative. Of interest, he had a
complete and rapid recovery with just supportive treat-
ment. This presentation could be explained by drug
toxicity. The initial drug screen was negative for amphe-
tamines. However, this was performed by routine im-
munoassay, which has a low sensitivity for detecting
MDMA. Severity of patient presentation is not necessarily
related to the ingested dose of MDMA [3,4]. Our patient
admitted taking multiple drugs along with “Molly”.
However, it is unlikely that the other substances ingested
concomitantly with “Molly” in our patient would have
contributed to a rapid onset multisystem organ failure.
MDMA toxicity is due to release of neurotransmitters
such as serotonin and dopamine causing hyperthermia,
seizures and muscle breakdown leading to renal failure
[1,2]. Cardiac toxicity can lead to CHF, arrhythmias and
myocardial infarction. The mechanism of cardiac toxicity
is not clearly understood but can be related to oxidative
stress from toxic metabolites of MDMA [5,6]. In addition,
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intravascular coagulation, liver failure and cerebrovascular
accidents [7,8]. The development of hyponatremia is
multifactorial and is thought to be primarily due to drug-
induced excessive thirst and secretion of arginine vaso-
pressin in the setting of fluid availability [6]. Various con-
stellations of these manifestations have resulted in case
reports of multisystem organ failure.
Several mechanisms of AKI associated with MDMA
have been proposed with the most common etiology being
seizure-precipitated rhabdomyolysis potentially accentua-
ted by volume depletion and hypotension. These cases
have pronounced levels of creatine kinase [6]. In our pa-
tient the cause of renal failure was not clear given only
mildly elevated creatine kinase levels. As shown in Table 1,
a creatine kinase level of 863 units/L was the highest level
recorded during his entire hospitalization. Retrospectively,
he most probably developed drug-induced renal artery
vasoconstriction leading to renal hypoperfusion and re-
versible acute tubular necrosis. Severe symptomatic hypo-
natremia is another serious complication of MDMA that
can present with mental status changes and seizures.
Although our patient presented with a seizure, it did not
appear to be related to hyponatremia nor to hyperthermia.
His confusion and agitation prior to intubation could be
interpreted as drug withdrawal but was more probably at-
tributable to encephalopathy in the setting of AKI and
hypoxemia. Acute respiratory failure in the context of
multisystem failure is due to acute lung injury in most
cases discussed in the literature [9]. In our patient this ap-
peared more related to fluid overload as a consequence of
CHF and AKI.
Based on a review of case reports, Liechti et al. de-
scribed two common presentations of ecstasy-related
death: the first being multiorgan failure precipitated by
hyperthermia and the second, hyponatremia-induced
brain edema [10]. Our patient had only a transient fever
spike with minimally decreased sodium; he does not ap-
pear to fit into either of these categories.
Contrary to the belief that “Molly” is pure MDMA, it
is often adulterated with so-called designer drugs, for ex-
ample methylenedioxypyrovalerone also known as bath
salts. These compounds inhibit norepinephrine-dopa-
mine reuptake and have a side-effect profile similar to
MDMA including AKI [11]. It is possible that our pa-
tient unknowingly ingested bath salts with “Molly”.
Conclusions
Physicians evaluating patients with increased sympathetic
activity and multisystem failure should consider drug in-
toxication in the differential especially when other etiolo-
gies become less likely. Rapid and complete reversal of
multisystem failure with supportive treatment only is sug-
gestive of drug intoxication. Often, as in our case, a fullhistory has to be elicited retrospectively. Therefore when
drug intoxication is considered a full toxicology screen
including MDMA levels should be obtained. Routine im-
munoassays for detecting amphetamines are unreliable in
detecting MDMA and more specific screening tests
should be requested. In patients with “Molly”-induced
organ failure it is difficult to predict which organs may fail
[12]. Pathophysiology and severity of organ failure may
vary.
“Molly” is abused in our community. Sadly, young
people who consume a single dose are at risk of serious
side effects because, unlike other drugs, the toxicity of
MDMA is not necessarily dose related [12]. In addition,
unknowing consumption of harmful adulterants may
also occur. “Molly” may be used in conjunction with
other recreational drugs with their own unique toxicities
[13]. Increased awareness of the dangers of “Molly” is
needed among the youth of our community.
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